Posted by Michael Wonder on 03 Feb 2020
FDA and FTC announce new efforts to further deter anti-competitive business practices, support competitive market for biological products to help Americans
3 February 2020 - The U.S. Food and Drug Administration and the Federal Trade Commission today signed a joint statement regarding enhanced collaboration in support of a robust marketplace for biological products, including the critical adoption of biosimilars and interchangeable products.
This joint statement describes key steps the agencies will take to address false or misleading promotion about biosimilars within their respective authorities and deter anti-competitive behaviour in this space.
